insurance changes to glp-1 drugs States cutting back on coverage of Ozempic and other for weight loss The GLP-1 Access Gap: Mapping
Description
Balancing innovation and affordability in anti-obesity medications: the role of an alternative weight-maintenance program
Daly T, Okholm S, Imbimbo BP
Measuring obesity is difficult
PMID: 3 GisondiPFostiniACFossIGirolomoniGTargherG
This affordable option, called CalRx insulin glargine pens, is interchangeable with some other once-a-day, long-acting insulins and is intended to provide a more affordable alternative for residents, particularly those who are uninsured or underinsured
